Stockscreener 앱 받기
17.40
3.12%
-0.56
시간 외 거래:
17.49
0.09
+0.52%
전일 마감가:
$17.96
열려 있는:
$17.96
하루 거래량:
1.57M
Relative Volume:
0.49
시가총액:
$1.82B
수익:
$2.48B
순이익/손실:
$-57.96M
주가수익비율:
-22.94
EPS:
-0.7585
순현금흐름:
$-453.97M
1주 성능:
+2.17%
1개월 성능:
-17.69%
6개월 성능:
-7.45%
1년 성능:
-84.15%
1일 변동 폭
$17.24
$18.09
1주일 범위
$17.24
$18.69
52주 변동 폭
$10.41
$111.20
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.40 | 1.88B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2025-12-09 | 개시 | Wedbush | Outperform |
| 2025-11-05 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-09-22 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Has Sarepta Therapeutics (SRPT) Fallen Too Far After Its Sharp Multi‑Year Share Price Slide? - simplywall.st
Sarepta Therapeutics to announce fourth quarter and full-year 2025 financial results - marketscreener.com
Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2025 Financial Results - TradingView
Sarepta Therapeutics to Report Q4 and Full-Year 2025 Financial Results - Intellectia AI
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results - Business Wire
New York State Common Retirement Fund Has $703,000 Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
(SRPT) Risk Channels and Responsive Allocation - Stock Traders Daily
New Zealand OKs Phase 1 trial of Huntington’s therapy SRP-1005 - huntingtonsdiseasenews.com
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), M3 (OtherMTHRF) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million - Yahoo Finance
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment - BioSpace
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN) - The Globe and Mail
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Is Sarepta (SRPT) Quietly Redefining Its Rare Disease Strategy With a Huntington’s Trial Bet? - simplywall.st
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up - BioSpace
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Sarepta Therapeutics announces clinical trial application approval for SRP-1005 in Huntington's disease - marketscreener.com
Sarepta (SRPT) Receives Green Light for Huntington's Disease Tri - GuruFocus
Sarepta receives approval to start SRP-1005 trial in New Zealand - TipRanks
Sarepta gets New Zealand approval for Huntington’s disease trial By Investing.com - Investing.com India
Sarepta gets New Zealand approval for Huntington’s disease trial - Investing.com
Sarepta Therapeutics Announces Clinical Trial Application Approval For SRP-1005 In Huntington’s Disease - TradingView
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease - Sarepta Therapeutics
SAREPTA gets approval to test Huntington's disease treatment in humans - StreetInsider
Jobs Data: Will Sarepta Therapeutics Inc outperform its industry peersJuly 2025 Rallies & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Assessing Sarepta Therapeutics (SRPT) Valuation After Positive Three Year EMBARK Data For Elevidys - Sahm
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion - MSN
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Closer Look at Its 5.38% Potential Upside - DirectorsTalk Interviews
AAV Gene Therapy Market is Thriving Worldwide | Novartis - openPR.com
Sarepta’s Elevidys Data Reshapes Duchenne Risk Profile For Long-Term Investors - Sahm
Sarepta’s Elevidys Data Underscore Long Term Duchenne Therapy Durability - Yahoo Finance
Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside? - Yahoo Finance
Institutional Owners May Take Dramatic Actions as Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Recent 3.7% Drop Adds to One-year Losses - 富途牛牛
Y Intercept Hong Kong Ltd Lowers Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags - MarketBeat
(SRPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Commit To Purchase Sarepta Therapeutics At $15, Earn 22.2% Annualized Using Options - Nasdaq
How Sarepta’s Long-Term ELEVIDYS Duchenne Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story - simplywall.st
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Sell Signal: Can Sarepta Therapeutics Inc. be recession proofTrade Risk Summary & Weekly Top Performers Watchlists - mfd.ru
Regenxbio Falls Most Ever After Tumor Found in Trial Participant - Bloomberg.com
Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Barclays - MarketBeat
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More - BioSpace
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD - The Globe and Mail
HC Wainwright Reiterates Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta (SRPT): Analyst Reiterates Sell Rating Due to Data Conce - GuruFocus
Sarepta eyes Elevidys sales comeback with positive Phase III data - Yahoo Finance
Sarepta Therapeutics (SRPT): Analyst Reiterates Sell Rating Toda - GuruFocus
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - BioSpace
Sarepta Therapeutics (SRPT) upgraded to buy: What does it mean for the stock? - MSN
Sarepta Therapeutics Elevidys Data Highlights Durable Duchenne Benefits And Risks - Sahm
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사렙타 테라퓨틱스 주식 (SRPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BEHRENS M KATHLEEN | Director |
Jan 27 '26 |
Option Exercise |
13.71 |
10,500 |
143,955 |
203,976 |
| Estepan Ian Michael | Chief Operating Officer |
Dec 16 '25 |
Sale |
22.31 |
13,187 |
294,202 |
193,300 |
1.24%
0.19%
자본화:
|
볼륨(24시간):